Media Coverage 16 Apr 2021 Courier Mail: “Brisbane Covid hope as ‘wonder drug’ trialled in US” Implicit Bioscience today announced its lead drug IC14 will be tested in a Phase 2 clinical trial in COVID-19 patients… Implicit Bioscience
Company News 12 Jan 2021 FDA Awards IC14 as Orphan Drug for MND The FDA has designated Brisbane biotech Implicit Bioscience’s biologic IC14 an Orphan Drug for the treatment of motor neurone disease. Implicit Bioscience
Company News 20 Dec 2020 US Defense Department Funds Program for IC14 in Neurotrauma The US Department of Defense has funded a USD 735,000 grant entitled “Danger Signalling, Traumatic Brain Injury (TBI), and Epileptogenesis”. Implicit Bioscience
Company News 15 Dec 2020 FDA Grants Approval for Heart Attack Trial The US Food and Drug Administration has issued a “Study May Proceed” letter approving the commencement of clinical study with… Implicit Bioscience
Company News 03 Jun 2020 FDA approves COVID-19 study On June 3, the US FDA approved an Investigative New Drug (IND) application for IC14 together with remdesivir in 300… Implicit Bioscience
Company News 16 Dec 2019 New research links IC14 target to dementia New research published in the world’s leading journal Neurology reports a link between higher levels of an inflammatory marker called sCD14 and… Implicit Bioscience
Company News 17 Sep 2019 Australian Immunotherapy Selected for Revolutionary US Clinical Trial Platform Debut An Australian immunotherapy drug will receive a huge boost when it is tested with four other new concepts across 54… Implicit Bioscience
